

PI 3-kinase p110 β siRNA (h): sc-37269

BACKGROUND

Phosphatidylinositol 3-kinase (PI 3-kinase) is composed of p85 and p110 subunits. p85 lacks PI 3-kinase activity and acts as an adapter, coupling p110 to activated protein tyrosine kinase. Two forms of p85 have been described (p85 α and p85 β), each possessing one SH3 and two SH2 domains. Various p110 isoforms have been identified. p110 α and p110 β interact with p85 α , and p110 α has also been shown to interact with p85 β *in vitro*. p110 δ expression is restricted to white blood cells. It has been shown to bind p85 α and β , but it apparently does not phosphorylate these subunits. p110 δ seems to have the capacity to autophosphorylate. p110 γ does not interact with the p85 subunits. It has been shown to be activated by α and $\beta\gamma$ heterotrimeric G proteins.

CHROMOSOMAL LOCATION

Genetic locus: PIK3CB (human) mapping to 3q22.3.

PRODUCT

PI 3-kinase p110 β siRNA (h) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see PI 3-kinase p110 β shRNA Plasmid (h): sc-37269-SH and PI 3-kinase p110 β shRNA (h) Lentiviral Particles: sc-37269-V as alternate gene silencing products.

For independent verification of PI 3-kinase p110 β (h) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-37269A, sc-37269B and sc-37269C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20 $^{\circ}$ C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20 $^{\circ}$ C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

PI 3-kinase p110 β siRNA (h) is recommended for the inhibition of PI 3-kinase p110 β expression in human cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

GENE EXPRESSION MONITORING

PI 3-kinase p110 β (C-8): sc-376641 is recommended as a control antibody for monitoring of PI 3-kinase p110 β gene expression knockdown by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) or immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-IgG κ BP-HRP: sc-516102 or m-IgG κ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker[™] Molecular Weight Standards: sc-2035, UltraCruz[®] Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use m-IgG κ BP-FITC: sc-516140 or m-IgG κ BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz[®] Mounting Medium: sc-24941 or UltraCruz[®] Hard-set Mounting Medium: sc-359850.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor PI 3-kinase p110 β gene expression knockdown using RT-PCR Primer: PI 3-kinase p110 β (h)-PR: sc-37269-PR (20 μ l, 604 bp). Annealing temperature for the primers should be 55-60 $^{\circ}$ C and the extension temperature should be 68-72 $^{\circ}$ C.

SELECT PRODUCT CITATIONS

- Hill, K.M., et al. 2010. The role of PI 3-kinase p110 β in Akt signaling, cell survival, and proliferation in human prostate cancer cells. *Prostate* 70: 755-764.
- Ye, Z.W., et al. 2011. Silencing p110 β prevents rapid depletion of nuclear pAkt. *Biochem. Biophys. Res. Commun.* 415: 613-618.
- Shao, G., et al. 2015. Lysine-specific demethylase 1 mediates epidermal growth factor signaling to promote cell migration in ovarian cancer cells. *Sci. Rep.* 5: 15344.
- Terzo, E.A., et al. 2019. SETD2 loss sensitizes cells to PI3K β and Akt inhibition. *Oncotarget* 10: 647-659.
- Palrasu, M., et al. 2020. Bacterial CagA protein compromises tumor suppressor mechanisms in gastric epithelial cells. *J. Clin. Invest.* 130: 2422-2434.
- Mazloumi Gavani, F., et al. 2021. Nuclear upregulation of class I phosphoinositide 3-kinase p110 β correlates with high 47S rRNA levels in cancer cells. *J. Cell Sci.* 134: jcs246090.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.